Compare Snowflake Inc (SNOW) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs Zimmer Biomet Holdings Inc — how do they compare? Snowflake Inc trades at $368.89 (market cap $121.15B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Snowflake Inc is far larger — about 7.1× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Snowflake Inc for 54 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SNOW | ZBH | |
|---|---|---|
Market Cap | $121.15B | $16.95B |
Volume | 3,986,549 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $356.47 | $103.98 |
52-Week Low | $121.11 | $79.58 |
Typical Hold Time | 54 Days | 89 Days |
Enterprise Value | $121.57B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $343.40, up 3.17% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth from $1.2B in 2022 to $3.63B in 2025, though it remains unprofitable with a -20.07% net margin. Recent earnings beats and a $3.75B convertible note offering highlight strategic positioning in the AI data cloud market. Analyst consensus is strongly bullish with 81% buy ratings and a $418 price target, representing 22% upside potential.
Snowflake presents a growth-over-profits investment case with expanding revenue and market leadership in data cloud services. Key opportunities include AI integration partnerships and enterprise adoption, while risks center on persistent losses, high valuation multiples (P/S 21.75), and competitive pressure from cloud giants. The stock's technical strength and Wall Street optimism suggest continued upside if execution matches growth expectations.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
